Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026)
Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -12.60% |
| 10 | Bioventus | 972.56 Mn | 943.11 Mn | 105.67 Mn | -23.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -23.38% |
| Mar 28, 2026 | 146.22% |
| Dec 31, 2025 | 96.50% |
| Sep 27, 2025 | 191.76% |
| Jun 28, 2025 | 71.07% |
| Mar 29, 2025 | -221.92% |
| Dec 31, 2024 | 86.25% |
| Sep 28, 2024 | 198.40% |
| Jun 29, 2024 | 40.45% |
| Mar 30, 2024 | -228.89% |
| Dec 31, 2023 | 136.58% |
| Sep 30, 2023 | -6,735.44% |
| Jul 1, 2023 | 267.30% |
| Apr 1, 2023 | 122.17% |
| Dec 31, 2022 | -66.57% |
| Oct 1, 2022 | -98.51% |
| Jul 2, 2022 | -83.04% |
| Apr 2, 2022 | -16.50% |
| Dec 31, 2021 | -48.45% |
| Oct 2, 2021 | -49.20% |